Validation of a XXXX @entity1911 (PC12)-based cell survival assay for determining biological potency of recombinant @entity1 nerve growth factor.

@entity1 @entity3538 @entity35 @entity1911
A method has been validated, according to the Guidelines of the @entity3538 ( @entity3538 ), for precise quantitation of the biological activity of recombinant @entity1 nerve growth factor (rhNGF) for lot release testing. The assay is based on the survival of a subclone of @entity35 @entity1911 PC12 cells (PC12-CF) in response to rhNGF. Cell survival is measured by monitoring the reduction, by living cells, of the alamarBlue dye into a red form which is highly fluorescent. The assay is simple, has high throughput (performed in 96-well microtiter plates) and shows reproducible dose-response curves in the concentration range of 0.2-50 ng/ml. The method was validated for its linearity, accuracy, precision, robustness, and to meet current regulatory requirements. The assay demonstrated good linearity, yielding a coefficient of determination of 0.9902. Sample recovery studies demonstrated an accuracy ranging from 96 to 98%. The repeatability of the assay and intermediate precision had coefficients of variation (CV) of <9%. The assay was stability-indicating since it was able to detect changes in rhNGF samples degraded by protease treatment and in a number of isolated rhNGF variants. Robustness was demonstrated by the relative insensitivity of the assay to small deliberate changes in key method parameters. The validation data, provided in this manuscript, indicate that the newly described bioassay for rhNGF is robust, accurate, precise, and suitable for lot release potency testing of rhNGF.
